Eli Lilly and Company’s Stock Price Plummets to $794.10, Witnessing a Sharp 11.66% Drop

Eli Lilly and Company (LLY)

794.10 USD -104.85 (-11.66%) Volume: 12.57M

Eli Lilly and Company’s stock price currently stands at 794.10 USD, experiencing a significant drop of -11.66% this trading session, with a trading volume of 12.57M. Despite today’s decline, the pharmaceutical giant’s stock maintains a positive year-to-date (YTD) performance, boasting a gain of +2.86%.

Latest developments on Eli Lilly and Company

Eli Lilly & reported a 45% increase in sales driven by high demand for its weight loss drugs, but the drugmaker had to cut its profit outlook after a deal related to cancer treatment. Despite beating earnings expectations and reaffirming its 2025 guidance, the stock price slipped. The company also entered into a pact with Creyon Bio for AI oligonucleotide development, with significant biobucks on the table. However, the stock faced a double downgrade, leading to a nosedive in its value. With Novo notching a coverage win for its obesity drug, Eli Lilly’s stock continued to sink as CVS dropped Zepbound from its preferred coverage. The CEO urged Trump to ease up on tariffs and negotiate trade deals, emphasizing the importance of responding to national security concerns around essential drugs. Despite a strong Q1 performance, the outlook cut and Novo’s deal with CVS overshadowed Eli Lilly’s success, causing shares to plunge.

A look at Eli Lilly and Company Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

According to the Smartkarma Smart Scores, Eli Lilly & Company seems to have a positive long-term outlook. With a high score in Momentum, the company is showing strong performance and growth potential. Additionally, Eli Lilly scores well in Growth, indicating promising prospects for expansion and development in the future. This suggests that the company may continue to thrive and innovate in the pharmaceutical industry.

Eli Lilly & Company also demonstrates resilience and stability with a score of 3 in Resilience. This indicates that the company is well-equipped to handle challenges and uncertainties, providing a sense of security for investors. While the Value score is not as high, Eli Lilly’s overall outlook appears to be favorable, especially with a decent score in Dividend. With its diverse range of pharmaceutical products for both humans and animals, Eli Lilly is positioned to maintain its presence in global markets and drive continued growth.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma